Why packaging compatibility testing is not a one-time event in topical pharmaceutical manufacturing

Packaging Compatibility Testing: A Lifecycle Requirement in Topical Manufacturing

In topical pharmaceutical manufacturing, packaging compatibility testing is far more than a regulatory checkbox—it’s an ongoing process that underpins product quality, patient safety, and clinical success. For topical drug products, where the formulation may include challenging excipients, unique actives, or sensitive delivery formats, the risk of interaction between product and packaging is significant. Physical, chemical, and microbiological stability all depend on appropriate container-closure systems that do not alter or degrade the product throughout its shelf life.

Consider the typical lifecycle of a topical formulation: initial bench-scale development, scale-up for clinical supplies, registration batch manufacturing, and ultimately commercial production. Each phase may use slightly different packaging materials or sources, often driven by supply chain realities or evolving regulatory feedback. Even minor changes in packaging components—such as switching from one HDPE tube supplier to another—can introduce new variables that affect compatibility.

Dow Development Labs, based in Petaluma, CA, routinely advises clients to view packaging compatibility testing as an evolving requirement, not a single milestone. Addressing compatibility at every stage helps to minimize downstream risks, support regulatory submissions, and safeguard patient outcomes. This article will explore why initial compatibility results may lose validity, what triggers repeat testing, the connection to stability studies, regulatory expectations, real-world consequences, and ongoing best practices.

For further reading, see Basics of Biocompatibility: Information Needed for Assessment by from the FDA.

Why Initial Compatibility Results May Not Remain Valid

A common misconception in topical drug development is that once the first set of packaging compatibility tests is complete, the work is done. In reality, early compatibility data are specific to the exact formulation, process, and packaging configuration tested at that moment. As the drug product moves through development, numerous factors can invalidate those initial results:

• Formulation Adjustments: Even minor changes to excipients, preservatives, or active concentrations can alter the product’s interaction with packaging materials. For example, increasing the ethanol content in a gel may enhance leachability from a laminate tube.
• Packaging Sourcing Changes: Switching suppliers for tubes, bottles, or caps—even if materials appear identical—can introduce subtle but critical differences in resin grades, plasticizers, or adhesives.
• Manufacturing Scale-Up: The stresses and exposures encountered at pilot or commercial scale may differ from lab runs, potentially revealing new compatibility challenges.
• Storage and Distribution Variability: Broader distribution networks and larger storage volumes can result in greater temperature and humidity excursions, which may impact extractables and leachables profiles.

For instance, a semi-solid ointment may show no visible interaction with a polypropylene jar at bench scale, but after switching to a commercial supplier, trace levels of antioxidants or slip agents from the jar could migrate into the product. These interactions typically remain undetected until repeat packaging compatibility testing is performed on the new configuration.

Triggers for Repeat Packaging Compatibility Testing in Topical Drug Programs

Multiple events in the lifecycle of a topical drug product may necessitate repeat packaging compatibility testing. Recognizing these triggers is crucial for avoiding delays, deviations, or regulatory hurdles.

• Formulation Modifications: Adjustments to pH, viscosity, excipient composition, or preservative systems.
• Packaging Material or Supplier Changes: Sourcing new tubes, bottles, jars, closures, or liners—even with the same nominal specifications.
• Scale-Up or Process Changes: Transitioning from lab scale to pilot or commercial manufacturing, or modifying filling/sterilization conditions.
• Regulatory Feedback: Agency requests for additional data or clarification on container-closure compatibility.
• Unexpected Stability Findings: Discovery of product degradation, discoloration, odor, or particulates during ongoing stability monitoring.
• Supply Chain Disruptions: Substitute packaging components required due to shortages or discontinuations.
• Market Expansion: Introduction to new regions with different environmental or distribution stresses.
• Labeling or Tamper Evidence Modifications: Changes that affect the container-closure system’s interaction with the product.

Each of these triggers can introduce new risks, making it best practice to proactively assess compatibility whenever such changes occur.

Stability Studies and Their Role in Ongoing Compatibility Assessment

Stability studies are a cornerstone of pharmaceutical development, and for topical drugs, they offer a continuous lens through which packaging compatibility is monitored. ICH guidelines outline requirements for long-term, intermediate, and accelerated stability testing, all of which are designed to simulate storage and distribution conditions the product will face in the real world.

During these studies, analysts assess not only the chemical and physical stability of the drug product but also look for signs of packaging interaction, such as:

• Appearance of leachables or extractables originating from the container
• Changes in product color, odor, or texture that may indicate migration or degradation
• Loss of potency or preservative efficacy
• pH drift associated with contact with packaging components

For example, an emulsion-based topical suspended in an aluminum tube may remain stable under room temperature but show visible discoloration at accelerated conditions, suggesting a reaction with the tube’s internal lacquer. Only through ongoing stability testing can such interactions be identified and managed before the product reaches patients.

Dow Development Labs routinely incorporates packaging compatibility testing within stability protocols, offering clients a continuous view of product-package interactions across different lots, packaging sources, and storage conditions.

Regulatory Expectations for Continuous Packaging Compatibility Evaluation

Regulatory agencies in the U.S., EU, and globally expect that container-closure compatibility is not a static, one-time assessment but a dynamic process that continues throughout the drug product’s lifecycle. FDA guidance, for instance, emphasizes the need for ongoing evaluation of extractables and leachables, especially when changes to packaging or formulation occur.

Sponsors are expected to:

• Document all packaging materials and sources in the regulatory submission (e.g., IND, NDA, ANDA, or 505(b)(2) application)
• Provide comprehensive compatibility data for each intended packaging configuration, including any alternatives or region-specific options
• Address any packaging changes post-approval with supplemental data, often requiring new or updated compatibility studies
• Monitor stability and compatibility throughout commercial distribution, reporting significant findings to regulatory agencies as required

Failure to maintain up-to-date compatibility data can result in regulatory delays, additional information requests, or even clinical hold. Agencies have increasingly scrutinized topical products for packaging interactions, particularly in complex formulations with known excipient-reactivity or where packaging innovation (e.g., metered-dose pumps, child-resistant closures) is involved.

Continuous attention to packaging compatibility testing is therefore a regulatory expectation, not just a development best practice.

Real-World Consequences of Treating Packaging Compatibility Testing as a One-Time Event

Treating packaging compatibility as a one-off event can have significant, sometimes costly, real-world consequences. Pharmaceutical and biotech companies have reported issues such as:

• Product Recalls: Unanticipated extractable or leachable substances, such as plasticizers or antioxidants, leading to product recalls after commercial launch.
• Stability Failures: Late-stage discovery of stability issues—such as active ingredient loss or preservative degradation—attributable to packaging interaction.
• Regulatory Delays: Agency requests for additional compatibility data delaying clinical trial initiation or commercial approval.
• Loss of Market Confidence: Healthcare providers and patients losing trust in a product due to visible packaging-related defects (e.g., discoloration, phase separation).
• Increased Development Costs: Needing to redo stability or clinical batches because of previously undetected packaging incompatibilities.

A well-documented example occurred when a topical corticosteroid cream, originally tested in polyethylene tubes, was later filled into laminate tubes from a new supplier. Despite matching specifications, the new laminate introduced a migratory component that interacted with the product, resulting in a recall and several months of investigation. Comprehensive, lifecycle-based compatibility testing could have detected this risk earlier, minimizing patient impact and financial loss.

Best Practices for Managing Packaging Compatibility Throughout the Drug Product Lifecycle

To effectively manage packaging compatibility and mitigate associated risks, pharmaceutical developers should incorporate the following practices throughout the lifecycle of a topical product:

1. Integrate Compatibility Into Change Control:
   • Include packaging compatibility as a formal criterion in all change control and supplier qualification processes.
2. Conduct Compatibility Testing at Each Key Milestone:
   • Perform compatibility assessments at preclinical, clinical, registration, and commercial stages—especially after formulation, packaging, or scale changes.
3. Embed Compatibility in Stability Protocols:
   • Design stability studies to monitor for packaging-related changes at all ICH-recommended timepoints and conditions.
4. Maintain Traceable Documentation:
   • Keep detailed records of all packaging sources, material specifications, and test results to support regulatory submissions and audits.
5. Proactively Reassess on Change Triggers:
   • Initiate new compatibility testing whenever triggered by supplier changes, supply chain disruptions, formulation tweaks, or regulatory feedback.
6. Engage Cross-Functional Teams:
   • Involve R&D, quality, regulatory, and supply chain stakeholders in compatibility planning and decision-making.
7. Leverage Experienced Partners:
   • Consider collaborating with experienced development labs, such as Dow Development Labs, to design and execute comprehensive compatibility programs aligned with your product’s specific needs.

These practices may help reduce unexpected failures, streamline regulatory review, and support a robust commercial launch.

How Dow Development Labs Supports Ongoing Packaging Compatibility Testing

Dow Development Labs (DDL) is experienced in supporting topical drug product development and understands that packaging compatibility testing is a recurring need, not a one-time step. DDL’s team works with clients to design compatibility protocols tailored to each phase of development, from initial formulation through commercial launch.

DDL can assist with:

• Developing and executing compatibility studies for a wide range of primary packaging materials, including tubes, jars, bottles, and pumps
• Integrating compatibility testing into ICH-compliant stability programs
• Assessing extractables and leachables in response to supplier changes or supply chain disruptions
• Providing documentation and technical justification to support regulatory submissions and agency queries
• Consulting on packaging material selection and change management strategies

By partnering with DDL, pharmaceutical and biotech sponsors can take a proactive approach to packaging compatibility—reducing downstream risk and supporting a smooth path from development to commercialization.

Ready to discuss your topical drug product’s packaging compatibility needs? Contact Dow Development Labs at 707-202-6965 to speak with a knowledgeable scientist about your next project.

Frequently Asked Questions

What is packaging compatibility testing in topical pharmaceuticals?

Packaging compatibility testing is the process of ensuring that the container or packaging material does not negatively interact with the topical drug product. This includes checking for chemical reactions, physical changes, or contamination that could affect the product's safety or effectiveness.

Why isn't packaging compatibility testing a one-time event?

Compatibility testing needs to be repeated throughout the product lifecycle because changes in packaging materials, suppliers, or even minor formulation tweaks can introduce new risks. Ongoing testing helps catch issues early and ensures consistent product quality and patient safety.

When should packaging compatibility testing be performed during development?

Testing should be conducted at every key stage—initial development, clinical trial scale-up, and commercial production—especially if there are changes in packaging suppliers or materials. This approach helps prevent unexpected interactions and supports successful regulatory submissions.

What can happen if packaging compatibility testing is overlooked?

Ignoring compatibility testing can lead to product degradation, reduced efficacy, contamination, or even recalls, all of which can harm patients and damage your reputation. Regular testing minimizes these risks and supports compliance with regulatory requirements.

How can I get support with packaging compatibility testing for my topical product?

Specialized labs like Dow Development Labs in Petaluma, CA, can guide you through the compatibility testing process and help you develop a robust plan. You can reach them at 707-202-6965 for expert advice tailored to your product stage and packaging needs.